Physician profile
Vincent C Lee
NPI 1689010878
$1,480.68
in general payments reported to CMS, 2019-2025
17 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.51 · 2020: $42.61 · 2021: $16.10 · 2022: $122 · 2023: $130 · 2024: $567 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $519.65 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Si-Bone, INC. | $252.76 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.25 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $108.80 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $82.50 | 2020-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $73.81 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.04 | 2025 | Caplyta |
| Pfizer INC. | $44.55 | 2025 | |
| Abbvie INC. | $32.96 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2024-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $27.10 | 2025 | |
| Exact Sciences Corporation | $24.93 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $21.29 | 2025 | Gemtesa |
| Bridgebio Pharma, INC. | $20.44 | 2025 | Attruby |
| Amgen INC. | $17.48 | 2025 | Repatha, Otezla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $17.28 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.29 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.